Is Allarity Therapeutics, Inc. (ALLR) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 6.8% / 30% | 98.0% / 30% | 11.2% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 6.8% / 33% | 98.0% / 33% | 11.2% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 6.0% / 33% | 86.2% / 33% | 9.8% / 33% | N/A | ✗ NOT HALAL |
| S&P | 6.8% / 33% | 98.0% / 33% | 11.2% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 6.0% / 33% | 86.2% / 33% | 9.8% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -122.6% | |
| Return on Assets (ROA) | -51.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$17M |
| Free Cash Flow | -$18M |
| Total Debt | $1M |
| Debt-to-Equity | 11.6 |
| Current Ratio | 2.3 |
| Total Assets | $23M |
Price & Trading
| Last Close | $1.07 |
| 50-Day MA | $1.06 |
| 200-Day MA | $1.19 |
| Avg Volume | 173K |
| Beta | 0.2 |
|
52-Week Range
$0.61
| |
About Allarity Therapeutics, Inc. (ALLR)
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs. The company develops drugs for the personalized treatment of cancer using drug specific companion diagnostics generated by its proprietary drug response predictor technology. Its lead drug candidate includes Stenoparib, a novel dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) that is being evaluated in a phase 2 clinical trial in patients with advanced and recurrent ovarian cancer. The company also develops stenoparib- DRP, a companion diagnostic product used in select patients for stenoparib treatment. Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Allarity Therapeutics, Inc. (ALLR) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Allarity Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Allarity Therapeutics, Inc.'s debt ratio?
Allarity Therapeutics, Inc.'s debt ratio is 6.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 6.0%.
What are Allarity Therapeutics, Inc.'s key financial metrics?
Allarity Therapeutics, Inc. has a market capitalization of $17M, trailing P/E ratio of 0.1. Return on equity stands at -122.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.